Asia Pacific Cell Therapy Market Size, Share, and COVID-19 Impact Analysis, By Therapy Type (Allogeneic Therapies, Autologous Therapies, Stem-Cell Therapies, Non-Stem Cell Therapies, and Others), By Therapeutic Area (Oncology, Cardiovascular Disease, Musculoskeletal Disorders, Dermatology, and Others), and Asia Pacific Cell Therapy Market Size Insights, Industry Trends, Forecast to 2035

Asia Pacific Cell Therapy Market Size Insights Forecasts to 2035

• The Asia Pacific Cell Therapy Market Size Was Estimated at USD 830.3 million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 21.84% from 2025 to 2035
• The Asia Pacific Cell Therapy Market Size is Expected to Reach USD 7294.24 million by 2035

According to a research report published by Spherical Insights & Consulting, the Asia Pacific cell therapy market size is anticipated to reach USD 7294.24 million by 2035, growing at a CAGR of 21.84% from 2025 to 2035. The market is driven by the region has seen strong grants for translational research, a surge in the need for regenerative therapies and an increase in chronic and ageing-related degenerative diseases.

Market Overview

Cell therapy is the application of live human cells (autologous, allogeneic, and engineered cell populations) in the clinics for restoration, repair, and replacement of damaged tissues, as well as the modulation of pathological immune responses. Cell therapies are living drugs and, therefore, their production involves complex logistics, a very strict identity requirement, and sometimes even individual patient batch production. CAR-T cell therapies are vital for blood cancers, and there are still trials going on for solid tumors. Stem cells are used in the treatment of heart disease, diabetes, autoimmune disorders, and gastrointestinal issues.

The Asia Pacific Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended ExCellThera's Zemcelpr favourably, and the Asia Pacific Commission gave the drug conditional marketing authorization for adult patients with hematologic malignancies requiring stem cell transplant but having no compatible donor. The treatment involves the fusion of the cord blood–derived stem cells that are expanded ex vivo through UM171, a patented small compound promoting stem cell self-renewal, with cells from the same unit that remain unchanged.

Report Coverage

This research report categorizes the market for the Asia Pacific Cell Therapy Market Size based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific cell therapy market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific cell therapy market.

Driving Factors

The Cell Therapy Market in Asia Pacific is driven by continuous public financial support for scientists and researchers. The Medical Research Council granted the cell and gene therapy catapult 90 million pounds to speed up processing and get ready for regulatory approval. The increasing number of chronic degenerative diseases in Asia Pacific is a major reason for the clinical use of regenerative cell-based treatments. Neurodegenerative diseases and, even more urgently, Alzheimer's Disease International claims that 9.1 million Asia Pacific are suffering from dementia, which is forecasted to double by the year 2050.

Restraining Factors

The Cell Therapy Market in Asia Pacific is restrained by the production of cell therapies is a very complex process that includes several different stages, such as upgrading and checking the quality of the cells, which all need the use of special machines and adhering to strict rules that will keep the cells alive and safe. Besides, every single person who can be treated by these methods, together with the rapid processing time, limits the products to be made in large quantities, thus requiring very good transportation, such as temperature-controlled carriage, to ensure the delivery takes place at the right time.

Market Segmentation

The Asia Pacific cell therapy market share is categorised into therapy type and therapeutic area.

• The autologous therapies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Asia Pacific Cell Therapy Market Size is segmented by therapy type into allogeneic therapies, autologous therapies, stem-cell therapies, non-stem cell therapies, and others. Among these, the autologous therapies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The cell therapy market in 2024 will be mainly composed of autologous cells, which will have about 62% share due to their numerous advantages like lower rejection challenges, more precise treatment choice, better engraftment, and less ethical issues. Autologous cell therapy consists of taking the cells from a patient and then altering them in a lab outside the body using gene editing or other methods.

• The oncology segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on therapeutic area, the Asia Pacific Cell Therapy Market Size is segmented into oncology, cardiovascular disease, musculoskeletal disorders, dermatology, and others. Among these, the oncology segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The cell therapy market accounted the 48% in 2024, with cell therapies being the main reason for this transformation in cancer treatment. The novel and targeted approaches that the disease has to face are the very ones that these therapies provide. This new and not to mention very effective way of dealing with the disease has given hope in identifying the right intervention that will work well among the various categories of tumors, pediatric, hematologic, solid cancers and genetic types.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific cell therapy market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                                                                                                            

• TC BioPharm
• Cellin Technologies
• 3P Biopharmaceuticals
• Cell-Easy
• Cellpoint
• Treefrog Therapeutics
• Tigen
• Selexis
• Ixaka
• Novartis
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Cell Therapy Market based on the below-mentioned segments:

Asia Pacific Cell Therapy Market, By Therapy Type

• Perfume & Cosmetics
• Wine & Spirits
• Fashion & Accessories
• Tobacco Products
• Electronics & Gifts
• Others

Asia Pacific Cell Therapy Market, By Therapeutic Area

• Oncology
• Cardiovascular Disease
• Musculoskeletal Disorders
• Dermatology
• Others